EntryPoint Capital LLC Acquires 112,210 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

EntryPoint Capital LLC increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 475.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 135,797 shares of the company’s stock after purchasing an additional 112,210 shares during the period. EntryPoint Capital LLC owned approximately 0.15% of Aquestive Therapeutics worth $483,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of AQST. Vanguard Group Inc. lifted its position in shares of Aquestive Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after buying an additional 82,958 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after purchasing an additional 90,543 shares during the last quarter. State Street Corp boosted its position in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the period. Janney Montgomery Scott LLC grew its holdings in Aquestive Therapeutics by 6.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock valued at $3,505,000 after purchasing an additional 61,200 shares during the last quarter. Finally, Harvey Capital Management Inc. raised its position in shares of Aquestive Therapeutics by 1,419.3% in the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AQST shares. Lake Street Capital decreased their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target on the stock. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Monday, March 10th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Trading Down 0.9 %

Shares of NASDAQ AQST opened at $3.22 on Wednesday. The firm has a market capitalization of $318.36 million, a price-to-earnings ratio of -7.16 and a beta of 2.76. Aquestive Therapeutics, Inc. has a one year low of $2.24 and a one year high of $5.80. The business has a fifty day simple moving average of $2.99 and a 200 day simple moving average of $3.98.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. On average, research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.